Article
Rheumatology
Hiroki Hayashi, Jiao Sun, Yuka Yanagida, Shota Yoshida, Satoshi Baba, Akiko Tenma, Masayoshi Toyoura, Sotaro Kawabata, Takako Ehara, Ryoko Asaki, Makoto Sakaguchi, Hideki Tomioka, Munehisa Shimamura, Ryuichi Morishita, Hiromi Rakugi, Tetsuya Tomita, Hironori Nakagami
Summary: This study aimed to assess the efficacy of an IL17A peptide-based vaccine on SpA manifestations in model rats. The results showed that the IL17A peptide-based vaccine successfully induced antibody production and suppressed the arthritis score and joint thickness. It also inhibited enthesitis, bone destruction, and new bone formation. The study suggests that the IL17A peptide-based vaccine may be a therapeutic option for SpA treatment.
Article
Rheumatology
Robert D. Inman, Denis Choquette, Majed Khraishi, Dafna D. Gladman, Shamiza Hussein, Drew Neish, Patrick Leclerc
Summary: This study aimed to describe the real-world use of Secukinumab (SEC) in Canadian patients with axSpA. The results showed that SEC was effective in treating axSpA, with improvements in disease activity observed in patients after 12 months of treatment.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Berkan Armagan, Levent Kilic, Bayram Farisogullari, Gozde Kubra Yardimci, Emre Bilgin, Ertugrul Cagri Bolek, Omer Karadag, Sule Apras Bilgen, Sedat Kiraz, Ihsan Ertenli, Umut Kalyoncu
Summary: This study evaluated the retention rate of secukinumab in r-AxSpA patients and identified predictive factors. The global retention rate of secukinumab was 55% at 12 months. Obesity was found to be associated with a lower risk of secukinumab discontinuation, while multiple TNFi usage increased the risk. This real-life analysis suggests that obesity may not be an adverse risk factor for secukinumab drug retention in r-AxSpA.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Medicine, General & Internal
Francisca Sivera, Victoria Nunez-Monje, Cristina Campos-Fernandez, Isabel Balaguer-Trull, Montserrat Robustillo-Villarino, Marta Aguilar-Zamora, Marta Garijo-Bufort, Juan Miguel Lopez-Gomez, Carolina Pena-Gonzalez, Isabel de la Morena, Diego Bedoya-Sanchis, Liliya Yankova-Komsalova, Arantxa Conesa-Mateos, Anna Martinez-Cristobal, Francisco Javier Navarro-Blasco, Jose Miguel Senabre-Gallego, Juan Jose Alegre-Sancho
Summary: This study provided real-world data on the use, effectiveness, and persistence of secukinumab in the treatment of axial spondyloarthritis. The results showed that secukinumab improved disease activity in patients with axSpA, especially in naive and second-line patients, and had high persistence rates up to 24 months.
FRONTIERS IN MEDICINE
(2023)
Article
Immunology
Rick Wilbrink, Anneke Spoorenberg, Suzanne Arends, Kornelis S. M. van der Geest, Elisabeth Brouwer, Hendrika Bootsma, Frans G. M. Kroese, Gwenny M. Verstappen
Summary: This study compared the composition of peripheral B-cell compartment in axSpA patients and pSS patients, revealing a significant increase in the frequency of CD21(low) B cells compared to healthy donors. This suggests an active involvement of B-cells in the pathogenesis of axSpA, contradicting previous beliefs.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Pedro M. Machado, Martin Schaefer, Satveer K. Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G. S. Saad, Christopher E. M. Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F. Mateus, Emily Sirotich, Enrique R. Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajao Martins, Helena Santos, Jonathan Dau, Jonathan N. Barker, Jonathan Hausmann, Kimme L. Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M. Pinheiro, Marcos David Zelaya, Maria de los Angeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S. Wallace, Zenas Z. N. Yiu, Jinoos Yazdany, Philip C. Robinson, Catherine H. Smith
Summary: This study investigated factors associated with severe COVID-19 in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis. The study found that age, sex, comorbidities, disease activity, and glucocorticoid use were associated with the severity of COVID-19. Additionally, later pandemic time periods, psoriasis, and the use of TNFi, IL17i, and IL-23i/IL-12+23i were associated with a reduced risk of severe COVID-19.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Zhixiu Li, Mohammad Kazim Khan, Sjef M. van der Linden, Bjorn Winkens, Peter M. Villiger, Heinz Baumberger, Hermine van Zandwijk, Muhammad Asim Khan, Matthew A. Brown
Summary: This study found that patients with ankylosing spondylitis (AS) have a higher mortality rate compared to the general population, and healthy individuals carrying the HLA-B27 gene also have a similar risk. Additionally, female patients have a lower life expectancy. However, in the overall European population, the presence of the HLA-B27 gene does not affect survival or the risk of death from cardiovascular disease.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Multidisciplinary Sciences
Hyemin Jeong, In Young Kim, Eun-Kyung Bae, Chan Hong Jeon, Kwang-Sung Ahn, Hoon-Suk Cha
Summary: The study showed that the selective estrogen receptor modulator lasofoxifene has a significant impact on disease activity of ankylosing spondylitis, inhibiting joint inflammation and enhancing bone mineral density. Additionally, lasofoxifene also influences the composition and diversity of gut microbiota.
SCIENTIFIC REPORTS
(2021)
Review
Rheumatology
Jurgen Braun, Uta Kiltz, Bjorn Buhring, Xenofon Baraliakos
Summary: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease characterized by inflammation and new bone formation in the axial skeleton. It is considered one disease with different courses, with two subtypes identified as radiographic and non-radiographic. The pathogenesis is not completely understood, but a strong link with human leukocyte antigen B27 has been identified. Treatment goals focus on controlling symptoms, inflammation, and preventing structural damage.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2021)
Review
Rheumatology
Victoria Navarro-Compan, Alexandre Sepriano, Bassel El-Zorkany, Desiree van der Heijde
Summary: Axial spondyloarthritis is a chronic inflammatory disease primarily affecting the axial skeleton, leading to symptoms such as chronic back pain and spinal stiffness. Diagnosis relies on recognizing clinical patterns and utilizing clinical, laboratory, and imaging features. Treatment options include non-steroidal anti-inflammatory drugs as first-line therapy, with biologics as a second-line option, showing efficacy in improving disease symptoms.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Pharmacology & Pharmacy
Javier Loricera, Eva Galindez-Aguirregoikoa, Ricardo Blanco
Summary: Secukinumab, the first IL-17A inhibitor approved for ankylosing spondylitis treatment, has shown efficacy and safety in patients with AS based on data from MEASURE clinical trials. The most common adverse event observed was mild infections, while mucocutaneous candidiasis was a relatively common side effect due to the role of IL-17A in mucocutaneous defense. Overall, Secukinumab remained generally well tolerated over the longer-term, making it a good treatment option for AS patients refractory to NSAIDs.
EXPERT OPINION ON DRUG SAFETY
(2021)
Article
Rheumatology
Atul Deodhar, Ricardo Blanco, Eva Dokoupilova, Stephen Hall, Hideto Kameda, Alan J. Kivitz, Denis Poddubnyy, Marleen van de Sande, Anna S. Wiksten, Brian O. Porter, Hanno B. Richards, Sibylle Haemmerle, Juergen Braun
Summary: The study demonstrates that secukinumab 150 mg provides significant and sustained improvement in patients with active nonradiographic axial spondyloarthritis (SpA) through 52 weeks. The safety profile is consistent with previous reports.
ARTHRITIS & RHEUMATOLOGY
(2021)
Article
Rheumatology
Ulf Lindstrom, Karin Bengtsson, Tor Olofsson, Daniela Di Giuseppe, Bente Glintborg, Helena Forsblad-d'Elia, Lennart T. H. Jacobsson, Johan Askling
Summary: Comparing the risk of anterior uveitis (AU) in patients with spondyloarthritis (SpA) treated with secukinumab versus tumor necrosis factor inhibitors (TNFi), it was found that secukinumab appears to be associated with a higher risk of AU compared to monoclonal TNFi, while the risk is similar to etanercept.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Health Care Sciences & Services
Wei Tu, Daan Nie, Yuxue Chen, Cheng Wen, Zhipeng Zeng
Summary: SAPHO syndrome is a disease with a wide range of dermatological and musculoskeletal manifestations, and its outcome has improved greatly by optimizing management. Secukinumab, a fully human monoclonal antibody targeting IL-17A, is approved for the treatment of autoimmune psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Review
Microbiology
Tianwen Huang, Yaoyu Pu, Xiangpeng Wang, Yanhong Li, Hang Yang, Yubin Luo, Yi Liu
Summary: Spondyloarthritis (SpA) is a rheumatic disease that causes joint inflammation. Metabolomic profiling studies have provided insights into etiological factors and biomarkers for SpA.
FRONTIERS IN MICROBIOLOGY
(2022)
Review
Rheumatology
Daniele Mauro, Ranjeny Thomas, Giuliano Guggino, Rik Lories, Matthew A. Brown, Francesco Ciccia
Summary: Ankylosing spondylitis (AS) is a chronic inflammatory disease with features of both autoimmune and autoinflammatory processes. While the innate immune system plays a dominant role in AS, factors such as the intestine and biomechanical elements may also contribute to the disease's pathogenesis. Studies suggest a combination of autoinflammation and autoimmunity in AS, with evidence supporting both hypotheses.
NATURE REVIEWS RHEUMATOLOGY
(2021)
Article
Rheumatology
Mark C. Hwang, MinJae Lee, Lianne S. Gensler, Matthew A. Brown, Amirali Tahanan, Mohammad H. Rahbar, Theresa Hunter, Mingyan Shan, Mariko L. Ishimori, John D. Reveille, Michael H. Weisman, Thomas J. Learch
Summary: This study identified four distinct patterns of spinal disease progression in ankylosing spondylitis patients. Factors associated with higher spinal disease burden groups include male gender, longer disease duration, elevated CRP and smoking history. Independent confirmation in other AS cohorts is needed to confirm these radiographic patterns.
Letter
Rheumatology
Zhixiu Li, Mohammad K. Khan, Peter M. Villiger, Sjef van der Linden, Matthew A. Brown, Muhammad A. Khan
ARTHRITIS CARE & RESEARCH
(2022)
Article
Medicine, Research & Experimental
Sarah M. Graff, Stephanie R. Johnson, Paul J. Leo, Prasanna K. Dadi, Matthew T. Dickerson, Arya Y. Nakhe, Aideen M. McInerney-Leo, Mhairi Marshall, Karolina E. Zaborska, Charles M. Schaub, Matthew A. Brown, David A. Jacobson, Emma L. Duncan
Summary: Maturity-onset diabetes of the young (MODY) is a heterogeneous group of monogenic disorders caused by impaired pancreatic beta cell function. A nonsynonymous coding variant in the KCNK16 gene has been linked to MODY, affecting potassium channel function and leading to reduced insulin secretion.
Article
Rheumatology
Satveer K. Mahil, Katie Bechman, Antony Raharja, Clara Domingo-Vila, David Baudry, Matthew A. Brown, Andrew P. Cope, Tejus Dasandi, Carl Graham, Thomas Lechmere, Michael H. Malim, Freya Meynell, Emily Pollock, Jeffery Seow, Kamila Sychowska, Jonathan N. Barker, Sam Norton, James B. Galloway, Katie J. Doores, Timothy I. M. Tree, Catherine H. Smith
Summary: Patients receiving methotrexate may have impaired humoral immunity to a single dose of the BNT162b2 vaccine, but not those receiving targeted biologics. Cellular immune responses are preserved in all groups. Real-world pharmacovigilance studies are needed to determine the clinical effectiveness of these findings.
LANCET RHEUMATOLOGY
(2021)
Article
Genetics & Heredity
Aideen M. McInerney-Leo, Jennifer West, Bettina Meiser, Malcolm West, Maree R. Toombs, Matthew A. Brown, Emma L. Duncan
Summary: This study explores the physical and psychological impacts of MFS on Aboriginal Australians. It found that MFS presents significant challenges in daily living, especially severe vision impairment contributing to social exclusion and psychological distress. As individuals age, concerns shift towards cardiac complications.
JOURNAL OF GENETIC COUNSELING
(2022)
Article
Rheumatology
Sjef M. van der Linden, Muhammad Asim Khan, Zhixiu Li, Heinz Baumberger, Hermine van Zandwijk, Kazim Khan, Peter M. Villiger, Matthew A. Brown
Summary: The occurrence of acute anterior uveitis (AAU) among first-degree relatives (FDRs) of axial spondyloarthritis (axSpA) patients should prompt screening for axSpA. The co-occurrence of chronic inflammatory back pain (CIBP) and pain/discomfort in the thoracic spine and anterior chest wall can further enhance clinical suspicion of axSpA among these FDRs.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Zhixiu Li, Sjef M. van der Linden, Muhammad Asim Khan, Heinz Baumberger, Hermine van Zandwijk, Mohammad Kazim Khan, Peter M. Villiger, Matthew A. Brown
Summary: The objective of this study is to assess heterogeneity in axial spondyloarthritis (axSpA) and its sources. The results suggest that women clinically diagnosed with axSpA but without radiographic sacroiliitis have distinct characteristics compared to men with non-radiographic axSpA.
Letter
Genetics & Heredity
Matthew A. Brown, Christopher Wigley, Susan Walker, Deborah Lancaster, Augusto Rendon, Richard Scott
AMERICAN JOURNAL OF MEDICAL GENETICS PART A
(2022)
Article
Rheumatology
Sjef M. van der Linden, Muhammad Asim Khan, Zhixiu Li, Heinz Baumberger, Hermine van Zandwijk, Mohammad Kazim Khan, Peter M. Villiger, Matthew A. Brown
Summary: The lifetime recurrence risk of axSpA is substantial for HLA-B27(+) FDRs, and disease severity and the gender of the proband's children are associated with the risk of developing axSpA.
Article
Rheumatology
Lauren K. Ridley, Mark C. Hwang, John D. Reveille, Lianne S. Gensler, Mariko L. Ishimori, Matthew A. Brown, Mohammad H. Rahbar, Amirali Tahanan, Michael M. Ward, Michael H. Weisman, Thomas J. Learch
Summary: This study investigated a subgroup of patients with ankylosing spondylitis (AS) who had long-standing disease and fused sacroiliac (SI) joints and found that females and males with early symptom onset had less radiographic damage in the SI joints. All 23 patients without syndesmophytes were HLA-B27 positive.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Jose Garrido-Mesa, Matthew A. Brown
Summary: The expansion of a restricted pool of CD8 lymphocytes is commonly found in AS patients, but only in a small proportion of healthy HLA-B27 carriers. These findings strongly support the theory that AS is driven by the presentation of antigenic peptides to the adaptive immune system by HLA-B27.
CURRENT RHEUMATOLOGY REPORTS
(2022)
Review
Genetics & Heredity
Xiu-Feng Huang, Matthew A. Brown
Summary: Uveitis, the most common form of intraocular inflammatory disease, can be classified into infectious and non-infectious types. Non-infectious uveitis includes various conditions such as AAU, BD, VKH disease, BSCR, and sarcoid uveitis, with genetic and environmental factors playing important roles in its pathogenesis. Studies have identified strong associations with HLA in uveitis, leading to potential future research directions.
GENES AND IMMUNITY
(2022)
Article
Rheumatology
Mark C. Hwang, MinJae Lee, Lianne S. Gensler, Michael M. Ward, Matthew A. Brown, Thomas J. Learch, Amirali Tahanan, Mohammad H. Rahbar, Mariko Ishimori, Michael H. Weisman, John D. Reveille
Summary: In this study, we found that changes in individual spinal mobility measures over a 2-year period are not reliably associated with increased, longitudinal AS-related spinal structural progression. Moreover, baseline mSASSS, sex, CRP, and disease duration were confirmed to be associated with AS-related structural spinal progression over time.
ACR OPEN RHEUMATOLOGY
(2021)
Article
Cell Biology
Camilla J. Williams, Zhixiu Li, Nicholas Harvey, Rodney A. Lea, Brendon J. Gurd, Jacob T. Bonafiglia, Ioannis Papadimitriou, Macsue Jacques, Ilaria Croci, Dorthe Stensvold, Ulrik Wisloff, Jenna L. Taylor, Trishan Gajanand, Emily R. Cox, Joyce S. Ramos, Robert G. Fassett, Jonathan P. Little, Monique E. Francois, Christopher M. Hearon, Satyam Sarma, Sylvan L. J. E. Janssen, Emeline M. Van Craenenbroeck, Paul Beckers, Veronique A. Cornelissen, Erin J. Howden, Shelley E. Keating, Xu Yan, David J. Bishop, Anja Bye, Larisa M. Haupt, Lyn R. Griffiths, Kevin J. Ashton, Matthew A. Brown, Luciana Torquati, Nir Eynon, Jeff S. Coombes
Summary: This study identified 12 novel genetic loci with suggestive association with (V)over dotO(2)peak response following exercise training. However, a polygenic predictor score created from these loci failed to accurately predict the (V)over dotO(2)peak response. Significant correlations were found for beta coefficients of variants in the study and validation, suggesting that with higher statistical power, more significant genetic associations may become apparent.
JOURNAL OF BIOMEDICAL SCIENCE
(2021)